Mitochon Pharmaceuticals, Inc.

Mitochon Pharmaceuticals, Inc. is a biotech startup founded in 2014, headquartered in the United States. The company's slogan "Harnessing the Power of Mitochondria to Create Resilient, Protective Cells in Neurodegeneration and Aging" reflects its focus on developing drugs that target mitochondria to address serious diseases with unmet medical needs. Their clinical programs primarily target neurodegenerative diseases such as Huntington’s Disease, Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s, Parkinson, and Traumatic Brain Injury (TBI). Mitochon's approach is centered around correcting mitochondrial physiology to pave the way for disease-modifying therapies. Their platform is based on mitochondrial enhancers that specifically target the mitochondria, delivering brain-penetrating therapy to stimulate compensatory pathways. The company's mechanism of action can be found on their website (MOA: link). Notably, Mitochon has received $1.60M in a Venture Round investment from Ben Franklin Technology Partners of Southeastern Pennsylvania in May 17, 2016. Led by industry executives with over 80 years of combined experience, the company is passionately committed to advancing breakthrough drug therapies for devastating diseases within the Biopharma, Biotechnology, and Pharmaceutical industries.